AbbVie and the Medicines Patent Pool have signed a voluntary licensing deal, enabling a generic version of the pharmaceutical company's Mavyret hepatitis C drug to be sold in poorer countries via royalty-free deals with generic drug makers. The deal is part of an effort by both companies to expand their business into developing countries, where they can sell cheaper versions of their drugs at lower prices than those available through traditional distribution channels.
AbbVie and the Medicines Patent Pool have signed a voluntary licensing deal, enabling a generic version of the pharmaceutical company's Mavyret hepatitis C drug to be sold in poorer countries via royalty-free deals with generic drug makers. However, the arrangement has been criticised for having limited availability in comparison with similar licensing agreements.